HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?

Abstract

Marked improvements in survival and health outcome for people infected with HIV have occurred since the advent of combination antiretroviral therapy over a decade ago. Yet HIV-associated neurocognitive disorders continue to occur with an alarming prevalence. This may reflect the fact that infected people are now living longer with chronic infection. There is mounting evidence that HIV exacerbates age-associated cognitive decline. Many middle-aged HIV-infected people are experiencing cognitive decline similar that to that found among much older adults. An increased prevalence of vascular and metabolic comorbidities has also been observed and is greatest among older adults with HIV. Premature age-associated neurocognitive decline appears to be related to structural and functional brain changes on neuroimaging, and of particular concern is the fact that pathology indicative of neurodegenerative disease has been shown to occur in the brains of HIV-infected people. Yet notable differences also exist between the clinical presentation and brain disturbances occurring with HIV and those occurring in neurodegenerative conditions such as Alzheimer's disease. HIV interacts with the aging brain to affect neurological structure and function. However, whether this interaction directly affects neurodegenerative processes, accelerates normal cognitive aging, or contributes to a worsening of other comorbidities that affect the brain in older adults remains an open question. Evidence for and against each of these possibilities is reviewed.

Figure 1

Change in delayed recall performance on the Hopkins Verbal Learning Test Revised (HVLT-R) as a function of age for HIV ⁺ and HIV ⁻ groups. The HIV⁺ group showed performance declines with increasing age, whereas the HIV⁻ group had either stable or slight improvements in recall over 1 year, showing a clear interaction between age and HIV effects on verbal recall. Results are displayed as means with 95% confidence bands. Change is defined as the difference between baseline and follow-up scores (12 months - 0 months).